Literature DB >> 16775324

Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses.

Kristina Abel1, Bapi Pahar, Koen K A Van Rompay, Linda Fritts, Clarissa Sin, Kimberli Schmidt, Roxana Colón, Mike McChesney, Marta L Marthas.   

Abstract

A vaccine to protect human immunodeficiency virus (HIV)-exposed infants is an important goal in the global fight against the HIV pandemic. Two major challenges in pediatric HIV vaccine design are the competence of the neonatal/infant immune system in comparison to the adult immune system and the frequent exposure to HIV via breast-feeding. Based on the hypothesis that an effective vaccine needs to elicit antiviral immune responses directly at the site of virus entry, the pattern of virus dissemination in relation to host immune responses was determined in mucosal and lymphoid tissues of infant macaques at 1 week after multiple oral exposures to simian immunodeficiency virus (SIV). The results show that SIV disseminates systemically by 1 week. Infant macaques can respond rapidly to virus challenge and mount strong innate immune responses. However, despite systemic infection, these responses are most pronounced in tissues close to the viral entry site, with the tonsil being the primary site of virus replication and induction of immune responses. Thus, distinct anatomic compartments are characterized by unique cytokine gene expression patterns. Importantly, the early response at mucosal entry sites is dominated by the induction of proinflammatory cytokines, while cytokines with direct antiviral activity, alpha/beta interferons, are only minimally induced. In contrast, both antiviral and proinflammatory cytokines are induced in lymphoid tissues. Thus, although infant macaques can respond quickly to oral viral challenge, the locally elicited immune responses at mucosal entry sites are likely to favor immune activation and thereby virus replication and are insufficient to limit virus replication and dissemination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775324      PMCID: PMC1488945          DOI: 10.1128/JVI.02240-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group.

Authors:  W T Shearer; T C Quinn; P LaRussa; J F Lew; L Mofenson; S Almy; K Rich; E Handelsman; C Diaz; M Pagano; V Smeriglio; L A Kalish
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

2.  Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.

Authors:  Koen K A Van Rompay; Kimberli A Schmidt; Jonathan R Lawson; Raman Singh; Norbert Bischofberger; Marta L Marthas
Journal:  J Infect Dis       Date:  2002-10-29       Impact factor: 5.226

3.  Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251.

Authors:  Koen K A Van Rompay; Jennifer L Greenier; Kelly Stefano Cole; Patricia Earl; Bernard Moss; Jonathan D Steckbeck; Bapi Pahar; Tracy Rourke; Ronald C Montelaro; Don R Canfield; Ross P Tarara; Christopher Miller; Michael B McChesney; Marta L Marthas
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells.

Authors:  E Maraskovsky; W F Chen; K Shortman
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

5.  Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity.

Authors:  M Giovarelli; A Santoni; C Jemma; T Musso; A M Giuffrida; G Cavallo; S Landolfo; G Forni
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

Review 6.  Animal models for perinatal transmission of pathogenic viruses.

Authors:  R M Ruprecht; C Fratazzi; P L Sharma; M F Greene; D Penninck; M Wyand
Journal:  Ann N Y Acad Sci       Date:  1993-10-29       Impact factor: 5.691

7.  Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.

Authors:  V M Hirsch; T R Fuerst; G Sutter; M W Carroll; L C Yang; S Goldstein; M Piatak; W R Elkins; W G Alvord; D C Montefiori; B Moss; J D Lifson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  A comparative immunological analysis of the oral mucosa in chronic graft-versus-host disease and oral lichen planus.

Authors:  T Mattsson; K G Sundqvist; A Heimdahl; G Dahllöf; P Ljungman; O Ringdén
Journal:  Arch Oral Biol       Date:  1992       Impact factor: 2.633

9.  Neonatal disease induced by SIV infection of the rhesus monkey (Macaca mulatta).

Authors:  R P Bohm; L N Martin; B Davison-Fairburn; G B Baskin; M Murphey-Corb
Journal:  AIDS Res Hum Retroviruses       Date:  1993-11       Impact factor: 2.205

10.  Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques.

Authors:  M L Marthas; K K van Rompay; M Otsyula; C J Miller; D R Canfield; N C Pedersen; M B McChesney
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

View more
  41 in total

1.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

3.  Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.

Authors:  Koen K A Van Rompay; Darius Babusis; Zachary Abbott; Yongzhi Geng; Kartika Jayashankar; Jeffrey A Johnson; Jonathan Lipscomb; Walid Heneine; Kristina Abel; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

4.  Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.

Authors:  Jinyan Liu; Hualin Li; M Justin Iampietro; Dan H Barouch
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

5.  Heightened cytotoxic responses and impaired biogenesis contribute to early pathogenesis in the oral mucosa of simian immunodeficiency virus-infected rhesus macaques.

Authors:  Michael D George; David Verhoeven; Sumathi Sankaran; Tiffany Glavan; Elizabeth Reay; Satya Dandekar
Journal:  Clin Vaccine Immunol       Date:  2008-12-17

6.  Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.

Authors:  Marta L Marthas; Koen K A Van Rompay; Zachary Abbott; Patricia Earl; Linda Buonocore-Buzzelli; Bernard Moss; Nina F Rose; John K Rose; Pamela A Kozlowski; Kristina Abel
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

Review 7.  Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?

Authors:  Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke
Journal:  ACS Chem Neurosci       Date:  2015-06-19       Impact factor: 4.418

Review 8.  The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies.

Authors:  Kristina Abel
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

9.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.

Authors:  Jeff Fairman; Joseph Moore; Mathieu Lemieux; Koen Van Rompay; Yongzhi Geng; John Warner; Kristina Abel
Journal:  Hum Vaccin       Date:  2009-03-14

10.  A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.

Authors:  Kristina Abel; Lisa Strelow; Yujuan Yue; Meghan K Eberhardt; Kimberli A Schmidt; Peter A Barry
Journal:  Vaccine       Date:  2008-08-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.